IL322253A - Chemical process - Google Patents

Chemical process

Info

Publication number
IL322253A
IL322253A IL322253A IL32225325A IL322253A IL 322253 A IL322253 A IL 322253A IL 322253 A IL322253 A IL 322253A IL 32225325 A IL32225325 A IL 32225325A IL 322253 A IL322253 A IL 322253A
Authority
IL
Israel
Prior art keywords
compound
formula
salt
metal
ester
Prior art date
Application number
IL322253A
Other languages
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL322253A publication Critical patent/IL322253A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

WO 2020/230100 PCT/IB2020/054629 CHEMICAL PROCESS Field of invention The present invention relates to a novel chemical process for the synthesis of the compound N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5- yl)pyridine-3-carboxamide.
Background of the invention The compound N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1 -yl]-5-(1 H- pyrazol-5-yl)pyridine-3-carboxamide, herein also referred as compound of formula (1), is a BCR-ABL (breakpoint cluster region-Abelson chimeric protein) tvrosine-kinase inhibitor. WO 2013/171639 A1 provides compounds of Formula (1) as useful in treating diseases which respond to inhibition of the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR- ABL1. The compound of Formula (1) is also known as (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide, or asciminib.
The compound of Formula (1), preparation of the compound of formula (1), and pharmaceutical compositions of the compound of formula (1) are originally described in WO 2013/171639 A1 as Example 9.
Nevertheless, there remains a need to provide improved processes for the preparation of the compound of formula (1), which are economically more efficient, safer, and better suited for full size production scale.
Description of the invention WO 2020/230100 PCT/IB2020/054629 The present invention is directed to an improved synthesis of compound of formula (1) and its purification, using less hazardous chemicals and/or reaction conditions, generating less waste and providing a reproducible process that is easier to handle on production scale. The present invention is also directed to a more efficient means of generating the compound of formula (1) at higher yield and in higher purity, generates less byproducts, and requires a lower catalyst loading compared to the methods disclosed in the prior art.
In this regard, the present invention is provided in the following aspects.
In accordance with a first aspect of the present invention, there is provided a process for producing the compound of formula (1), or a salt, solvate, stereoisomer, complex, co-crystal, ester, or oxazoline thereof, comprising the step of reacting the compound of formula (2), ->OH (2),or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof; and the compound of formula (3), or 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-boronic acid, pinacol ester with an alkali or alkaline salt in the presence of a metal complex catalyst to obtain the compound of formula (1) or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof, preferably to obtain compound of formula (1) is in its free carboxylic acid form.
WO 2020/230100 PCT/IB2020/054629 In the process, according to first aspect, the metal complex catalyst may be a metal precursor and a ligand or a pre-formed metal complex catalyst comprising a metal M and a ligand.
The metal M may be selected from Cu (copper) and Pd (palladium). Preferably the metal M is Pd.
The metal precursor may be selected from M(OAc)2, M2(dba)3, [M(C3H5)CI]2 (allyl metal chloride dimer), M(TFA)2, M(MeCN)2CI2, MCI2, [(cinnamyl)MCI]2, [MCI]2 (metal chloride), and M(acac)2. Preferably the metal precursor is [MCI]2 (metal chloride).
The ligand may be selected from Cy3P, (2-MeOPh)3P, P(tBu)2-n-PrSO2H, Q-phos (1,2,3,4,5- pentaphenyl-T-(di-tert-butylphosphino)ferrocene) , CataCXium ABn (Did- adamantyl) benzylphosphine), CataCXium A (Di(1-adamantyl)-n-butylphosphine), and S-Phos (2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl). Preferably, the ligand is S-Phos.
The pre-formed metal complex catalyst may be composed of the metals as ligands as defined above oris selected from [(o-tol)3P]2PdCI2] [t-Bu3PPdBr]2 / Pd-113, (dtbpf)PdCI2 / Pd-118, PEPPSI, PdCI2(PPh3)2, Pd(tBu2PhP)2, Pd(dppf)CI2 - CH2CI2, [(t-Bu)3P]Pd(0), CataCXium C, Pd(tBu2PhP)2(Pd-122), Pd(dppf)CI2 - CH2CI2 (Pd-106), (2-MeOPh)3P/ Pd2(dba)3, and PdCI2(Amphos)2/ Pd-132. Preferably, the pre-formed metal complex catalyst is selected from (dtbpf)PdCI2 (Pd-118), Pd(tBu2PhP)2(Pd-122), Pd(dppf)CI2 - CH2CI2 (Pd-106) and (2-MeOPh)3P/ Pd2(dba)3.
The alkali or alkaline salt may be selected from Na2CO3, CS2CO3, K3PO4, KF, and K2CO3. Preferably, the alkaline salt is K2CO3.
WO 2013/171639 A1, Example 9 describes a similar process in Stage 9.5 whereby the pre- formed metal complex catalyst Pd(PPh3)2CI2 and alkali salt K3PO4 in toluene are used to yield intermediate methyl 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)-1 H- pyrazol-5-yl)nicotinate. However, when scaled up to 3 kg, the synthesis resulted in incomplete conversion of starting materials and required additional amounts of the compound of formula (3) and K3PO4 to complete the reaction, thus not suitable for large scale manufacturing of the compound of formula (1).
WO 2020/230100 PCT/IB2020/054629 The reaction provided herein provides a high rate of conversion [> 98 % conversion to the compound of formula (1)] and a high purity [> 96 % purity measured as in-process control (IPC)]. The compound of formula (1) is obtained in high yield (> 80%).An advantage of this process over the prior art process is the reduction of byproducts produced and catalyst loading required fora more complete conversion of starting materials. Therefore, the process of the invention suitable for scaling up for commercial production purposes.In accordance with a second aspect of the invention, there is provided the process according to first aspect, further comprising the step of reacting the compound of formula (4) (4),or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof, preferablythe compound of formula (4) is in its free methyl ester form; with the compound of formula (5), to obtain the compound of formula (6) (6), WO 2020/230100 PCT/IB2020/054629 or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof, preferably the compound of formula (6) is in its free carboxylic acid form.
WO 2013/171639 A1, Example 9 describes a similar process in alternate Stage 9.1 by substituting a compound of formula (4) with 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro- 2H-pyran-2-yl)-1H-pyrazol-5-yl)nicotinic acid in NMM and combining with HOBtH2O and EDCIHCI in THF. However, 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)- H-pyrazol-5-yl)nicotinic acid was found difficult to crystallize, extract, and deliver consistent yield from the reaction. The synthesis also resulted in problematic impurities that are difficult to eliminate and negatively impacted yield.
An advantage of the process disclosed herein over the prior art process is that it avoids the problems found with 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H- pyrazol-5-yl)nicotinic acid and delivers consistent yield of the compound of formula (6). Therefore, the process of the invention is suitable for scaling up for commercial production purposes.
Examples Example 1: Step D2 + D3 -> D4 DC,qH24N4O372.42Basic procedure: A mixture of (R)-methyl 5-bromo-6-(3-hydroxypyrrolidin-1-yl)nicotinate (45.6 kg, D2), 1-1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-boronic acid, pinacol ester (50.5 kg, D3), and K2CO3 (41.8 kg) in toluene (282 mb) was added to a dry vessel. The suspension was stirred and water was added. PdCI2(dtbpf) (500 g) was added and the suspension was stirred at DC11H13BrN2O301.14 WO 2020/230100 PCT/IB2020/054629 about 50 °C until full conversion was achieved. After reaction completion, QuadraSil MP was added to the reaction mixture. The solid residues were removed by filtration over activated charcoal filter and the filter residue was washed with toluene, potable water and again with toluene. The organic and aqueous phases were separated and the aqueous layer was washed with toluene. The combined organic layers were washed with sodium chloride solution, dried using [Na2SO4] and evaporated in situ to provide methyl 6-((R)-3- hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)nicotinate (D4). Yield of D4 was estimated to be about 54 kg D4 / kg D2 (~ 95 %).
Example 2: Step D4 + D5 -> D6 C19H24N4O4372.42 C25H26CIF2N504533.95 To an empty vessel, a solution of sodium hydroxide (15.8 kg) and water was added to a mixture of 31.6 kg 4-(chlorodifluoromethoxy)aniline HCI (D5) in methyltetrahydrofuran (3kg) and the reaction mixture was stirred at around 25 °C. The biphasic mixture was separated and the organic phase was washed twice with water. The organic phase was concentrated by distillation, followed by addition of fresh methyltetrahydrofuran (2 x 148 kg) to obtain a concentrated solution of 4-(chlorodifluoromethoxy)aniline in methyltetrahydrofuran.
To the 10-20% solution of 660 kg of methyl 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro- 2H-pyran-2-yl)-1 H-pyrazol-5-yl)nicotinate (D4) in toluene, methyltetrahydrofuran (239 kg) was added and the solution was concentrated by distillation. To this concentrated solution, 148 kg of concentrated solution of D5 in methyltetrahydrofuran was added. To the obtained a mixture, 20% potassium tert-butoxide (258 kg) in tetra hydrofuran (169 kg) was dosed at around 25 °C. After reaction completion, aqueous sodium chloride solution (602 kg) was added and biphasic mixture was separated. The organic phase was extracted with aqueous WO 2020/230100 PCT/IB2020/054629 sodium chloride (602 kg) solution. The organic layer was filtered over activated charcoal filter. The solvent was exchanged by distillation from methyltetrahydrofuran to isopropanol. To this solution, seed crystals of N-(4-(Chlorodifluoromethoxy)phenyD-6-((R)-3- hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)nicotinamide (0.16 kg, D6) were added, followed by n-heptane (1274 kg). D6 was collected by filtration, washed with a mixture of n-heptane and isopropanol and dried under vacuum. Yield of D6 was estimated to be about 79-87 % of D6 based on amount of D3 charged.
D6C25H26CIF2N5O4533.95 Al C20H1gCIF2N5O; 449.84To a suspension of N-(4-(Chlorodifluoromethoxy)phenyl)-6-((R)-3-hydroxypyrrolidin-1-yl)-5- (1-(tetrahydro-2H-pyran-2-yl)-1 H-pyrazol-5-yl)nicotinamide (39.1kg, D6) in methanol (3kg), 37% HCI solution (9 kg) was added at 220C (pH < 1). The clear solution was then stirred for 1 h at 22 °C (IRC). The mixture was then quenched with 30% NaOH (4 kg) (pH = 10). Water was added to the mixture and the pH was adjusted to 2.5 to 3.0 by the addition of 30% NaOH. The solution was filtered over an active charcoal filter and then the pH was adjusted to 3.0 - 3.5 by the addition of more 30% sodium hydroxide before seeding with N-(4- (Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide (0.027kg, A1). A final pH adjustment to pH 7.5 - 9.0 was performed by the addition of ca. 1% sodium hydroxide solution resulting in precipitation of the product. The suspension was cooled to 10 °C and stirred before the product A1 was isolated by filtration, washed with a 4:mixture of water/methanol and dried. Yield of A1 was estimated to be about 76%.
Example 4: A1 -> A1a Example 3: Step D6 -> A1 WO 2020/230100 PCT/IB2020/054629 449.84C20H18CIF2N5O3-HCI449.84 + 36.46A mixture of N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol- 5-yl)nicotinamide (29.2 kg, AD, methanol (190 kg), and 37% hydrochloric acid (7 kg) is heated to about 50 °C and the resulting solution was filtered. The first portion of t-butyl methyl ether TBME (146 kg) and seed crystals of N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3- hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide hydrochloride (0.26 kg, A1a) were added at about 50 °C to the filtrate. The second portion of TBME (271 kg) was added and the suspension cooled to about 0 °C and stirred to allow for completion of crystallization. A1a was collected by filtration, washed with a mixture of TBME (78 kg) and methanol (9 kg) and dried under vacuum. Yield of A1a was estimated to be about 96%.

Claims (3)

WO 2020/230100 PCT/IB2020/054629 -9- Claims
1. A process for producing the compound of formula (1), or a salt, solvate, stereoisomer, complex, co-crystal, ester, or oxazoline thereof, comprising the step of reacting the compound of formula (2), ->OH (2),or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof; and the compound of formula (3), with an alkali or alkaline salt in the presence of a metal complex catalyst to obtain the compound of formula (1) or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof.
2. The process according to claim 1, wherein the metal complex catalyst is a metal precursor and a ligand or is a pre-formed metal complex catalyst comprising a metal M and a ligand, and wherein the metal M is selected from Cu and Pd;wherein the metal precursor is selected from M(OAc)2, M2(dba)3, [M(C3H5)CI]2 (allyl metal chloride dimer), M(TFA)2, M(MeCN)2CI2, MCI2, [(cinnamyl)MCI]2, and M(acac)2;wherein the ligand is selected from Cy3P, (2-MeOPh)3P, P(tBu)2-n-PrSO2H, Q-phos, CataCXium ABn, CataCXium A and S-Phos; WO 2020/230100 PCT/IB2020/054629 - 10- wherein the pre-formed metal complex catalyst is composed of the metals as ligands as defined above oris selected from [(o-tol)3P]2PdCI2] [t-Bu3PPdBr]2 / Pd-113, (dtbpf)PdCI2 / Pd-118, PEPPSI, PdCI2(PPh3)2, Pd(tBu2PhP)2 / PD-122, Pd(dppf)CI2 ■ CH2CI2/ PD-106, [(t-Bu)3P]Pd(0), CataCXium C, PdCI2(Amphos)2 / Pd-132, (2- MeOPh)3P/ Pd2(dba)3, and S-Phos Pd(OAc)2; andwherein the alkali or alkaline salt is selected from Na2CO3, CS2CO3, K3PO4, KF and K2CO3
3. A process according to claim 1 or 2, further comprising the step of reacting the compound of formula (4), (4),or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof, with the compound of formula (5), or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof.
IL322253A 2019-05-16 2020-05-15 Chemical process IL322253A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848869P 2019-05-16 2019-05-16
US201962929995P 2019-11-04 2019-11-04
PCT/IB2020/054629 WO2020230100A1 (en) 2019-05-16 2020-05-15 Chemical process

Publications (1)

Publication Number Publication Date
IL322253A true IL322253A (en) 2025-09-01

Family

ID=70775450

Family Applications (2)

Application Number Title Priority Date Filing Date
IL287919A IL287919B2 (en) 2019-05-16 2020-05-15 Chemical process
IL322253A IL322253A (en) 2019-05-16 2020-05-15 Chemical process

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL287919A IL287919B2 (en) 2019-05-16 2020-05-15 Chemical process

Country Status (11)

Country Link
US (1) US11236070B2 (en)
EP (1) EP3969445B1 (en)
JP (1) JP7620572B2 (en)
KR (1) KR102875297B1 (en)
CN (1) CN114096529A (en)
AU (1) AU2020275137B2 (en)
CA (1) CA3140119A1 (en)
ES (1) ES3014254T3 (en)
IL (2) IL287919B2 (en)
SI (1) SI3969445T1 (en)
WO (1) WO2020230100A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022206937A1 (en) * 2021-04-01 2022-10-06 苏州晶云药物科技股份有限公司 New crystal form of hydrochloride of pyrazole-substituted nicotinamide compound and preparation method therefor
CN116135851B (en) * 2021-11-17 2025-09-23 武汉众诚康健生物医药科技有限公司 Aromatic amine compound and its application
CN114369085B (en) * 2021-12-27 2023-01-03 武汉九州钰民医药科技有限公司 Preparation method of Asciminib hydrochloride
EP4615831A1 (en) * 2022-11-10 2025-09-17 Synthon B.V. Crystalline form of asciminib hydrochloride

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2117662A1 (en) 1971-04-10 1972-10-19 Farbwerke Hoechst AG, vormals Meister Lucius & Brüning, 6000 Frankfurt Phenylurea derivatives, their production and use as herbicides
JPH02104571A (en) 1988-10-13 1990-04-17 Kanegafuchi Chem Ind Co Ltd Production of n-benzylpyrrolidine derivative
JPH02212469A (en) 1989-02-10 1990-08-23 Kanegafuchi Chem Ind Co Ltd Production of n-benzylpyrrolidine derivative or its salt
US5739342A (en) 1997-03-03 1998-04-14 Abbott Laboratories Process for the preparation of nicotinic acids
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
GB0309631D0 (en) 2003-04-28 2003-06-04 Bayer Cropscience Ag Novel process for the preparation of 2-aminomethylpyridine derivatives
EP1674455A1 (en) 2004-12-21 2006-06-28 Bayer CropScience S.A. Process for the preparation of a 2-ethylaminopyridine derivative
ES2326280T3 (en) 2005-04-06 2009-10-06 F. Hoffmann-La Roche Ag DERIVATIVES OF PIRIDIN-3-CARBOXAMIDE AS INVESTED AGONISTS OF CB1.
WO2009151991A1 (en) 2008-06-11 2009-12-17 Merck & Co., Inc. Pyrazole derivatives useful as inhibitors of faah
US20120101282A1 (en) 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
JP2013095742A (en) 2011-11-07 2013-05-20 Manac Inc Method of producing bromopyridine derivative
KR20150008406A (en) 2012-05-15 2015-01-22 노파르티스 아게 Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
ES2670601T3 (en) 2012-05-15 2018-05-31 Novartis Ag Benzamide derivatives for the inhibition of the activity of ABL1, ABL2 and BCR-ABL1
CN104119238B (en) 2013-04-26 2016-09-21 金凯(辽宁)化工有限公司 A kind of preparation method of 4-(a chlorine difluoro-methoxy) aniline
DK3120852T3 (en) * 2015-01-30 2019-07-29 Taiho Pharmaceutical Co Ltd PREVENTIVE AND / OR THERAPEUTIC AGENT FOR IMMUNE DISEASES
MY185488A (en) 2015-04-09 2021-05-19 Orion Corp Process for the preparation of androgen receptor antagonists and intermediates thereof
TWI726900B (en) 2015-08-04 2021-05-11 美商陶氏農業科學公司 Process for fluorinating compounds
KR101830372B1 (en) 2015-09-01 2018-02-20 삼성전자주식회사 Refrigerator
EP3416949A1 (en) * 2016-02-18 2018-12-26 Solvay Sa Process for the manufacture of carboxamides
KR101825065B1 (en) * 2016-05-24 2018-02-05 한국화학연구원 Pharmaceutical composition for inducing the degradation of ALK protein and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
US11353435B2 (en) 2018-05-24 2022-06-07 Iowa State University Research Foundation, Inc. Zwitterionic compounds as gas chromatographic column stationary phases
LT3841101T (en) 2018-08-24 2023-06-26 Bayer Aktiengesellschaft Method for preparing 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine

Also Published As

Publication number Publication date
SI3969445T1 (en) 2025-05-30
KR20220009415A (en) 2022-01-24
EP3969445B1 (en) 2024-11-27
CA3140119A1 (en) 2020-11-19
KR102875297B1 (en) 2025-10-23
AU2020275137A1 (en) 2021-12-16
JP2022532232A (en) 2022-07-13
ES3014254T3 (en) 2025-04-21
US20200361903A1 (en) 2020-11-19
IL287919B2 (en) 2026-01-01
IL287919A (en) 2022-01-01
IL287919B1 (en) 2025-09-01
WO2020230100A9 (en) 2024-08-22
EP3969445A1 (en) 2022-03-23
CN114096529A (en) 2022-02-25
JP7620572B2 (en) 2025-01-23
US11236070B2 (en) 2022-02-01
WO2020230100A1 (en) 2020-11-19
AU2020275137B2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP7620572B2 (en) Chemical Process
EP2687510B1 (en) Method for preparing 2,3-dichloropyridine
WO2010091877A2 (en) Process for producing ambrisentan
KR101420892B1 (en) Process for the preparation of Imatinib and intermediates thereof
CN107922385B (en) CGRP receptor antagonists
CA2988594C (en) Methods of making protein deacetylase inhibitors
JP2024037935A5 (en)
TW202527952A (en) Synthetic method
KR20160144402A (en) Novel manufacturing process for triazine, pyrimidine and pyridine derivatives
CZ203394A3 (en) Process for preparing fibrinogen receptor antagonizing matters
RU2820241C2 (en) Chemical method
EA016832B1 (en) Process for the preparation of 5-(2-ethyl-2,3-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof
CN110023316A (en) Prepare the chemical method of imidazo pyrrolidinone derivatives and its intermediate
WO2021009034A1 (en) 3-[2(r)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-1h-pyrimidine-2,4(1h,3h)-dione hydrochloride salt (i) in solid form, process for preparing same, and use thereof in the synthesis of elagolix
HK40061249A (en) Process for the preparation of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide
HK40061249B (en) Process for the preparation of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide
AU2016387566A1 (en) An improved process for the preparation of Regorafenib
JP7373241B2 (en) Method for producing pyrimidinyl bipyridine compounds and intermediates therefor
CN109810052B (en) Simple and convenient preparation method of high-selectivity apatinib
HUP0001596A2 (en) Process for the preparation of 5-(aminomethyl)-2-chloropyridine derivatives
JP2022517411A (en) Method for preparing tetrahydropyridopyrimidines
KR102389718B1 (en) Method For Preparing Indole Or Indazole Compound
CA2367410C (en) Novel process for the preparation of 1-phenyl-2-(2-piridyl)ethanamine
CN106588841B (en) The method for synthesizing 2,3- dihydro -1- benzofuran -4- formaldehyde
CN117964546B (en) A preparation method of niraparib intermediate